Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWWRW4 is a peptide antagonist of formyl peptide receptor 2 (FPR2; IC50 = 0.23 µM) and FPR3, previously known as FPR-like 1 (FPRL1) and FPRL2, respectively.1,2 It inhibits increases in intracellular calcium and chemotaxis induced by the FPR1 and FPR2 agonist WKYMVm (Item No. 33589) in RBL-2H3 cells expressing FPR2 and by the FPR3 agonist F2L in isolated human monocytes when used at a concentration of 10 µM. WRW4 (10 µM) also prevents the production of superoxide induced by amyloid-β (1-42) (Aβ42; Item No. 20574) in isolated human neutrophils.1 In vivo, WRW4 (1 mg/kg) increases lung edema and bronchoalveolar lavage fluid (BALF) protein levels in the absence and presence of the antibiotic ceftriaxone (Item No. 18866) in a mouse model of acute lung injury induced by S. pneumoniae.3
WARNING This product is not for human or veterinary use.
1. Identification of peptides that antagonize formyl peptide receptor-
2. Trp-
3. Inhibition of the lipoxin A4 and resolvin D1 receptor impairs host response to acute lung injury caused by pneumococcal pneumonia in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 320(6), L1085-L1092 (2021).